Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption (McGlynn, Petrick and El-Serag, 2021). HCC occurs in approximately 85% of patients with cirrhosis of the liver, a crucial element in the development of HCC. HCC is nearly three times as common in men than women, possibly due to higher infection with HBV and HCV, higher alcohol and cigarette consumption on average, or higher iron levels in men (Nevola et al., 2023).

Scope

The model includes a 10-year epidemiological forecast for the diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent cases of HCC. Diagnosed incident cases are segmented by age (starting from 18 up to 85 years and older by 5-year age groups) and sex. Additionally, the diagnosed incident cases of HCC are segmented by BCLC stage, Child Pugh stage, HKLC stage, HCC risk factors (hepatitis B, hepatitis C, MASLD/MASH, alcohol), cirrhotic vs non-cirrhotic, and biomarkers. Additionally, the model incudes all-time diagnosed prevalent cases of HCC segmented by BCLC Stage.

Reasons to Buy

The HCC Epidemiology series will allow you to –

Develop business strategies by understanding the trends shaping and driving the global HCC markets.

Quantify patient populations in the global HCC markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.

Understand the magnitude of the HCC population by age, sex, BCLC stage, Child-Pugh stage, HKLC stage, risk factors, cirrhotic and non-cirrhotic HCC, and biomarkers.

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

2. Executive Summary

3. Disease Overview

3.1. Background

3.2. Risk Factors and Comorbidities

4. Epidemiological Forecast

4.1. Diagnosed Incident Cases of HCC, N, All Ages, Men and Women, 2024─34

4.2. Age-Specific Trends in Diagnosed Incident Cases of HCC, N, Men and Women, 2024

4.3. Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024

4.4. Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024

4.5. Trends of Diagnosed Incident Cases of HCC, N, All Ages, 2014─34

4.6. Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024

4.7. Diagnosed Incident Cases of HCC by Child Pugh Stage, N, All Ages, 2024

4.8. Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage, N, All Ages, 2024

4.9. Diagnosed Incident Cases of HCC by Risk Factor, N, All Ages, 2024

4.10. Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic, N, All Ages, 2024

4.11. Diagnosed Incident Cases of HCC by Biomarker, N, All Ages, 2024

4.12. Five-Year Diagnosed Prevalent Cases of HCC, N, All Ages, Men and Women, 2024─34

4.13. All-time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024

5. Sources and Methodology

5.1. Sources and Methodology for HCC Incidence

5.2. Diagnosed Incident Cases of HCC

5.3. Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage

5.4. Diagnosed Incident Cases of HCC by Child Pugh Stage

5.5. Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage

5.6. Diagnosed Incident Cases of HCC by Japan Integrated Staging Stage (Japan only)

5.7. Diagnosed Incident Cases of HCC by China Liver Cancer Stage (China only)

5.8. Diagnosed Incident Cases of HCC by Risk Factors

5.9. Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic

5.10. Diagnosed Incident Cases of HCC by Biomarkers

5.11. Five-Year Diagnosed Prevalent Cases of HCC

5.12. All-Time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage

6. Discussion

6.1. Epidemiological Forecast Insight

6.2. Strengths and Limitations

7. Appendix

7.1. Bibliography

7.2. About the Authors

8. Contact Us

Table

Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage, N, All Ages, 2024

Diagnosed Incident Cases of HCC by Biomarker, N, All Ages, 2024

Figures

Diagnosed Incident Cases of HCC, N, All Ages, Men and Women, 2024─34

Age-Specific Trends in Diagnosed Incident Cases of HCC, N, Men and Women, 2024

Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024

Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024

Trends of Diagnosed Incident Cases of HCC, N, All Ages, 2014─34

Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024

Diagnosed Incident Cases of HCC by Child Pugh Stage, N, All Ages, 2024

Diagnosed Incident Cases of HCC by Risk Factor, N, All Ages, 2024

Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic, N, All Ages, 2024

Five-Year Diagnosed Prevalent Cases of HCC, N, All Ages, Men and Women, 2024─34

All-time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035 in real time.

  • Access a live Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.